Get the Stockscreener App
14.29
3.93%
0.54
Mesoblast Ltd Adr stock is traded at $14.29, with a volume of 178.17K.
It is up +3.93% in the last 24 hours and down -11.46% over the past month.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
See More
Previous Close:
$13.75
Open:
$13.93
24h Volume:
178.17K
Relative Volume:
0.73
Market Cap:
$1.86B
Revenue:
$65.48M
Net Income/Loss:
$-94.46M
P/E Ratio:
-19.38
EPS:
-0.7375
Net Cash Flow:
$-71.18M
1W Performance:
+1.49%
1M Performance:
-11.46%
6M Performance:
-1.79%
1Y Performance:
-26.83%
1-Day Range:
$13.93
$14.38
1-Week Range:
$13.41
$14.38
52-Week Range:
$13.05
$21.50
Mesoblast Ltd Adr Stock (MESO) Company Profile
Compare MESO vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MESO
Mesoblast Ltd Adr
|
14.29 | 1.86B | 65.48M | -94.46M | -71.18M | -0.7375 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mesoblast Ltd Adr Stock (MESO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-25 | Upgrade | Jefferies | Hold → Buy |
| Jul-18-25 | Downgrade | Jefferies | Buy → Hold |
| Dec-23-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-24-24 | Upgrade | Maxim Group | Hold → Buy |
| Aug-29-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-23-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-31-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-07-23 | Downgrade | Maxim Group | Buy → Hold |
| Aug-04-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-04-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-09-23 | Initiated | William Blair | Outperform |
| Dec-06-22 | Downgrade | Jefferies | Buy → Hold |
| Sep-06-22 | Initiated | Piper Sandler | Overweight |
| Apr-07-21 | Upgrade | Maxim Group | Hold → Buy |
| Dec-22-20 | Downgrade | Maxim Group | Buy → Hold |
| Dec-04-20 | Downgrade | Chardan Capital Markets | Neutral → Sell |
| Oct-22-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-14-20 | Reiterated | Maxim Group | Buy |
| May-28-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-31-19 | Resumed | H.C. Wainwright | Buy |
| Mar-22-18 | Downgrade | Credit Suisse | Neutral → Underperform |
| Feb-28-18 | Reiterated | Cantor Fitzgerald | Buy |
| Aug-31-17 | Initiated | Oppenheimer | Outperform |
| Jun-08-17 | Initiated | Cantor Fitzgerald | Buy |
View All
Mesoblast Ltd Adr Stock (MESO) Latest News
Mesoblast (MESO) Slips 1.68% to $14.08 as Shares Pull Back From Recent HighsSocial Sentiment - siam.in
Mesoblast (NASDAQ: MESO) Secures FDA Approval for TIBA Potency Assay in Ryoncil Production - Kalkine Media
MEOBF Form 4 FilingsMESOBLAST LTD SEC Form 4 - Stock Titan
Stevanato Group S.p.A. (STVN) Stock Price & News - Syfe
Mesoblast LimitedADR Key Financial Ratios – Valuation, Profitability & More - Value Research
Mesoblast LimitedADR Peer Comparison – Compare with Others - Value Research
Jupiter Neurosciences, Inc. Warrants (JUNSW) Peer Comparison – Compare with Others - Value Research
Arena Pharmaceuticals Inc (ARNA) Peer Comparison – Compare with Others - Value Research
Mesoblast Limited Files Annual Form 20-F with US SEC for Fiscal Year Ended June 30, 2026 - Kalkine
Earnings call transcript: Mesoblast posts $115 million in FY2026 revenue, stock slips - Investing.com
Mesoblast (NASDAQ: MESO) gives director 875,000 incentive options - stocktitan.net
Mesoblast (MESO) Latest: Falls 2.47% to $17.00 in the Current Update; Price Levels: Support at $16.15 and Resistance at $17.85 Frame the Range for the Current SessionAnchored VWAP - careplusvn.com
Mesoblast (MESO) Latest: Falls 2.47% to $17.00 in the Current Update; Price Levels: Support at $16.15 and Resistance at $17.85 Frame the Range for the Current SessionPullback Trade - dars.gov.et
Mesoblast (MESO) Momentum: Ends Up by 1.56% at $16.93; Next Session: Price Remains Between $16.08 Support and $17.78 ResistanceLinear Regression - careplusvn.com
Mesoblast (MESO) Momentum: Ends Up by 1.56% at $16.93; Next Session: Price Remains Between $16.08 Support and $17.78 ResistanceZero Lag EMA - dars.gov.et
Mesoblast Targets $10 Billion Market With Regenerative Back Pain Treatment - Sahm
H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Movi - Benzinga
Mesoblast Shares Jump 8.82% on ASX as Biotech Rebounds From Friday's Sharp Selloff Tied to State Street Filing - International Business Times Australia
ETFs Investing in Mesoblast Limited Sponsored ADR Stocks - tradingview.com
MESO Q1 2026 Earnings: EPS Slightly Misses Estimates on Pre-Revenue Loss, Shares Rise 2.97% - careplusvn.com
MESO Q1 2026 Earnings: EPS Slightly Misses Estimates on Pre-Revenue Loss, Shares Rise 2.97%Positive Surprise Momentum - www.dars.gov.et
Why Mesoblast (NASDAQ:MESO) Sees NASDAQ Composite Spotlight Now? - Kalkine Media
MESO Q1 2026 Earnings: EPS Misses Estimates, Stock DeclinesEarnings Revision Downgrade - careplusvn.com
MESO Q1 2026 Earnings: EPS Misses Estimates, Stock DeclinesSlow Growth Warning - dars.gov.et
MESO Q1 2026 Earnings: EPS Misses Estimates, Stock DeclinesProfit Announcement - dars.gov.et
Mesoblast Shares Decline Nearly 5% as Key Support Levels TestedComposite Profile - dars.gov.et
Mesoblast Shares Decline Nearly 5% as Key Support Levels TestedFactor ETF Flow - careplusvn.com
Mesoblast Limited (ASX:MSB) Heats Up Again as Biotech Investors Watch Its Next Move - Kalkine
Mesoblast (ASX: MSB) Slips as Investors Monitor Ryoncil Growth and Product Pipeline - Kalkine
ETFs Investing in Mesoblast Limited Sponsored ADR Stocks - TradingView
Mesoblast Limited (MESO) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
What Triggered Today's Move in the Mesoblast (ASX:MSB) Share Price? - Kalkine
Mesoblast (ASX:MSB) Shares Give Back Ground After a Sharp Rally - Kalkine
Daily Brief Health Care: First Wave BioPharma , NeuroSpectrum Insights, Mesoblast Ltd, Know Labs , Zoetis Inc, CTT Pharmaceutical Holdings, Oncolytics Biotech, ATAI Life Sciences NV and more - Smartkarma
Daily Brief Australia: Genesis Minerals, Perpetual Ltd, Mesoblast Ltd, BHP Group Ltd, Pacific Niugini, D3 Energy, Noble Helium and more - Smartkarma
PayPal, Veradermics, Alibaba And Other Big Stocks Moving Higher On Wednesday - Benzinga
Why Is Mesoblast Stock Up Today? - Kalkine
Mesoblast Limited Announces ASX Quotation for 2.25 Million Shares Issued via Employee Share Option Plan - Kalkine Media
Is Mesoblast (ASX:MSB) Trading Within Its 52-Week Price Range? - Kalkine
Mesoblast Issues 2.25 Million Ordinary Shares Under Employee Share Option Plan - Kalkine
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain - GlobeNewswire Inc.
Mesoblast reaches 300-patient enrollment in back pain trial - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
SK Hynix Nasdaq debut: $26.5 billion ADR listing sets record - Yahoo Finance
Mesoblast Reports Strong RYONCIL® Revenue, Exceeding Projections - Sharecafe
Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026 - GlobeNewswire Inc.
Degenerative Disc Disease Market Statistics Expected to Experience Major Growth by 2036, According to DelveInsight | Mesoblast, DiscGenics, Biosplice Therapeutics, BIOPHARM GmbH, Yuhan, Histogen - Barchart.com
Mesoblast (ASX:MSB): The Stem Cell Therapy Company on the Cusp of Commercial Reality - Kalkine
ASX Biotech Stocks to Watch in July 2026 - Kalkine
Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs - GlobeNewswire Inc.
Mesoblast Ltd Adr Stock (MESO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mesoblast Ltd Adr Stock (MESO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| George Gregory | Director |
Apr 10 '26 |
Buy |
1.48 |
2,324,072 |
3,439,627 |
8,324,072 |
| George Gregory | Director |
Apr 10 '26 |
Buy |
1.48 |
2,324,072 |
3,439,627 |
8,324,072 |
| George Gregory | Director |
Apr 09 '26 |
Buy |
1.44 |
1,586,890 |
2,277,350 |
13,586,890 |
| George Gregory | Director |
Apr 09 '26 |
Buy |
8.59 |
1,981,890 |
17,015,467 |
13,586,890 |
| George Gregory | Director |
Apr 04 '26 |
Buy |
1.42 |
4,000,000 |
5,680,000 |
12,000,000 |
2.10%
1.98%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):